Financial
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
Foundation Medicine
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongOwned by Roche (ROG.SW)
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | CHF 61.5bn | +2.0% | CHF 21.8bn | CHF 13.8bn | Roche group |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Foundation Medicine found in HSH's search of the last 24 months.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Foundation Medicine found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Mar 2026: Foundation Medicine began a US Class 2 recall of three lots of a sequencing reagent used with FoundationOne CDx, after a possible increase in phasing that could cause false-positive BARD1 variant calls; affected units were quarantined for replacement.
Contract performance
May–Jun 2026: the FDA approved FoundationOne CDx as a companion diagnostic for several new cancer therapies, including tepotinib (MET NSCLC) and inavolisib (PIK3CA breast cancer). No contract disputes found.
Competitors
No competitors linked yet.